Russell Investments Group Ltd. boosted its position in Abbott Laboratories (NYSE:ABT – Free Report) by 15.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,590,548 shares of the healthcare product maker’s stock after buying an additional 209,676 shares during the period. Russell Investments Group Ltd. owned approximately 0.09% of Abbott Laboratories worth $157,311,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of ABT. Farther Finance Advisors LLC boosted its position in shares of Abbott Laboratories by 14.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock worth $8,339,000 after purchasing an additional 10,431 shares in the last quarter. Juncture Wealth Strategies LLC bought a new stake in Abbott Laboratories in the 3rd quarter valued at about $658,000. Aureus Asset Management LLC raised its stake in Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after buying an additional 66,422 shares during the period. Thompson Investment Management Inc. raised its stake in Abbott Laboratories by 786.0% during the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock worth $1,276,000 after buying an additional 12,474 shares during the period. Finally, Clear Harbor Asset Management LLC bought a new position in Abbott Laboratories in the second quarter worth approximately $4,889,000. Institutional investors own 75.18% of the company’s stock.
Insider Transactions at Abbott Laboratories
In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president directly owned 100,791 shares of the company’s stock, valued at $11,691,756. The trade was a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of brokerages have commented on ABT. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, October 22nd. BTIG Research lowered their target price on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Citigroup cut their target price on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a report on Thursday, October 22nd. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.32.
Read Our Latest Research Report on Abbott Laboratories
Abbott Laboratories Stock Performance
Shares of ABT opened at $108.59 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The stock has a 50 day moving average price of $103.93 and a two-hundred day moving average price of $101.74. The firm has a market capitalization of $188.08 billion, a P/E ratio of 40.52, a P/E/G ratio of 1.90 and a beta of 0.54. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned $1.30 earnings per share. Equities analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Further Reading
- Five stocks we like better than Abbott Laboratories
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
